|Day Low/High||91.73 / 93.01|
|52 Wk Low/High||62.55 / 97.86|
Don't worry about missing anything, we haven't solved the bond conundrum and the evidence says we get to 3% with selloffs on the way.
I added to two positions Tuesday, as growth catalysts are in play this earnings season.
The biotech sector has seen a big rally, but there are still opportunities.
Currency traders see the Trump administration boosting manufacturing via a weak dollar.
It's hard to understand the magnitude of the change.
The revenue and profit gains from some of the biggest technology companies like Amazon AMZN, Alphabet GOOGL and Microsoft MSFT show that valuations aren't so stretched.
The ECB's super dovish message was good for the markets.
U.S. futures point a higher open following earnings beats from Amazon, Alphabet and Microsoft after the bell on Thursday.
The market is off to a decent start as investors try to digest scores of first-quarter earnings reports. Bristol-Myers Squibb is just one of many large-cap drug and biotech companies reporting today. BMY shares are up as earnings and revenue easily ...
It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today. Biotech stalwarts Amgen and Celgene posted mixed results, while AbbVie seems to have beat both top- and ...
Biotech investors should keep a close eye on the progress in this huge potential market.
It's pretty normal to have profit-taking after such a strong first quarter.
Icahn may have a tough time finding interest in this behemoth.
Would get drugs to market faster and possibly more cheaply.
Carrot-stick 'arrangement' with biotech is a fair tradeoff but will produce winners and losers.
Value stocks will extend their outperformance over growth stocks that began last year.
On Friday, investors will get quarterly results from American Airlines and the release of fourth quarter gross domestic product.
Deals already are popping up, and we'll soon have earnings reports from the industry giants.